Cachectic skeletal muscle response to a novel bout of low-frequency stimulation

Journal of Applied Physiology

Volumn 116, Issue 8, 2014, Pages 1078-1087

  Puppa, Melissa J ^a   Murphy, E Angela ^b   Fayad, Raja ^a   Hand, Gregory A ^a   Carson, James A ^a  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Cachexia; Contraction; Low frequency stimulation; Mitochondria; Skeletal muscle

Indexed keywords

CYTOCHROME C; DNA BINDING PROTEIN; HIGH MOBILITY GROUP PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MESSENGER RNA; NRF1 PROTEIN, MOUSE; NUCLEAR RESPIRATORY FACTOR 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PPARGC1A PROTEIN, MOUSE; PYRROLIDINE DERIVATIVE; PYRROLIDINE DITHIOCARBAMIC ACID; STAT3 PROTEIN; STAT3 PROTEIN, MOUSE; TFAM PROTEIN, MOUSE; THIOCARBAMIC ACID DERIVATIVE; TRANSCRIPTION FACTOR;

ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CACHEXIA; DISEASE MODEL; DRUG EFFECTS; ELECTROTHERAPY; GENE EXPRESSION REGULATION; GENETICS; HAND STRENGTH; HUMAN; MALE; METABOLISM; MOUSE; MUSCLE CONTRACTION; MUTANT MOUSE STRAIN; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; SKELETAL MUSCLE; TUMOR SUPPRESSOR GENE;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; CACHEXIA; CYTOCHROMES C; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; ELECTRIC STIMULATION THERAPY; GENE EXPRESSION REGULATION; GENES, APC; HAND STRENGTH; HIGH MOBILITY GROUP PROTEINS; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MUSCLE CONTRACTION; MUSCLE, SKELETAL; NUCLEAR RESPIRATORY FACTOR 1; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA COACTIVATOR 1-ALPHA; PPAR GAMMA; PYRROLIDINES; RNA, MESSENGER; STAT3 TRANSCRIPTION FACTOR; THIOCARBAMATES; TRANSCRIPTION FACTORS;

EID: 84901207738     PISSN: 87507587     EISSN: 15221601     Source Type: Journal    
DOI: 10.1152/japplphysiol.01270.2013     Document Type: Article

References (51)

1. Acharyya S, Guttridge DC. Cancer cachexia signaling pathways continue to emerge yet much still points to the proteasome. Clin Cancer Res 13: 1356-1361, 2007.
2. Atherton PJ, Babraj J, Smith K, Singh J, Rennie MJ, Wackerhage H. Selective activation of AMPK-PGC-1alpha or PKB-TSC2-mTOR signaling can explain specific adaptive responses to endurance or resistance training-like electrical muscle stimulation. FASEB J 19: 786-788, 2005.
3. Baar K, Wende AR, Jones TE, Marison M, Nolte LA, Chen M, Kelly DP, Holloszy JO. Adaptations of skeletal muscle to exercise: rapid increase in the transcriptional coactivator PGC-1. FASEB J 16: 1879-1886, 2002.
4. Bakkar N, Wang J, Ladner KJ, Wang H, Dahlman JM, Carathers M, Acharyya S, Rudnicki MA, Hollenbach AD, Guttridge DC. IKK/NF-kappaB regulates skeletal myogenesis via a signaling switch to inhibit differentiation and promote mitochondrial biogenesis. J Cell Biol 180: 787-802, 2008.
5. Baltgalvis KA, Berger FG, Pena MM, Davis JM, Muga SJ, Carson JA. Interleukin-6 and cachexia in ApcMin/+ mice. Am J Physiol Regul Integr Comp Physiol 294: R393-R401, 2008.
6. Baltgalvis KA, Berger FG, Pena MM, Davis MJ, White JP, Carson JA. Activity level, apoptosis, and development of cachexia in Apc-(Min/+) mice. J Appl Physiol 109: 1155-1161, 2010.
7. Bergeron R, Ren JM, Cadman KS, Moore IK, Perret P, Pypaert M, Young LH, Semenkovich CF, Shulman GI. Chronic activation of AMP kinase results in NRF-1 activation and mitochondrial biogenesis. Am J Physiol Endocrinol Metab 281: E1340-E1346, 2001.
8. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
9. Brozinick JT Jr, Etgen GJ Jr, Yaspelkis BB 3rd, Ivy JL. Contraction-activated glucose uptake is normal in insulin-resistant muscle of the obese Zucker rat. J Appl Physiol 73: 382-387, 1992.
10. Carson JA, Baltgalvis KA. Interleukin 6 as a key regulator of muscle mass during cachexia. Exerc Sport Sci Rev 38: 168-176, 2010.
11. Cunningham JT, Rodgers JT, Arlow DH, Vazquez F, Mootha VK, Puigserver P. mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex. Nature 450: 736-740, 2007.
12. D'Souza D, Lai RY, Shuen M, Hood DA. mRNA stability as a function of striated muscle oxidative capacity. Am J Physiol Regul Integr Comp Physiol 303: R408-R417, 2012.
13. Deans C, Wigmore SJ. Systemic inflammation, cachexia and prognosis in patients with cancer. Curr Opin Clin Nutr Metab Care 8: 265-269, 2005.
14. Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, Jatoi A, Kalantar-Zadeh K, Lochs H, Mantovani G, Marks D, Mitch WE, Muscaritoli M, Najand A, Ponikowski P, Rossi Fanelli F, Scham-belan M, Schols A, Schuster M, Thomas D, Wolfe R, Anker SD. Cachexia: a new definition. Clin Nutr 27: 793-799, 2008.
15. Fentem PH. ABC of sports medicine. Benefits of exercise in health and disease. BMJ 308: 1291-1295, 1994.
16. Fernandez-Marcos PJ, Auwerx J. Regulation of PGC-1alpha, a nodal regulator of mitochondrial biogenesis. Am J Clin Nutr 93: 884S-890S, 2011.
17. Hayashi T, Hirshman MF, Kurth EJ, Winder WW, Goodyear LJ. Evidence for 5' AMP-activated protein kinase mediation of the effect of muscle contraction on glucose transport. Diabetes 47: 1369-1373, 1998.
18. He HJ, Zhu TN, Xie Y, Fan J, Kole S, Saxena S, Bernier M. Pyrrolidine dithiocarbamate inhibits interleukin-6 signaling through impaired STAT3 activation and association with transcriptional coactivators in hepatocytes. J Biol Chem 281: 31369-31379, 2006.
19. Hood DA, Irrcher I, Ljubicic V, Joseph AM. Coordination of metabolic plasticity in skeletal muscle. J Exp Biol 209: 2265-2275, 2006.
20. Kennedy JW, Hirshman MF, Gervino EV, Ocel JV, Forse RA, Hoenig SJ, Aronson D, Goodyear LJ, Horton ES. Acute exercise induces GLUT4 translocation in skeletal muscle of normal human subjects and subjects with type 2 diabetes. Diabetes 48: 1192-1197, 1999.
21. King PA, Betts JJ, Horton ED, Horton ES. Exercise, unlike insulin, promotes glucose transporter translocation in obese Zucker rat muscle. Am J Physiol Regul Integr Comp Physiol 265: R447-R452, 1993.
22. Lai RY, Ljubicic V, D'Souza D, Hood DA. Effect of chronic contractile activity on mRNA stability in skeletal muscle. Am J Physiol Cell Physiol 299: C155-C163, 2010.
23. Maddocks M, Byrne A, Johnson CD, Wilson RH, Fearon KC, Wilcock A. Physical activity level as an outcome measure for use in cancer cachexia trials: a feasibility study. Support Care Cancer 18: 1539-1544, 2010.
24. McClung JM, Judge AR, Powers SK, Yan Z. p38 MAPK links oxidative stress to autophagy-related gene expression in cachectic muscle wasting. Am J Physiol Cell Physiol 298: C542-C549, 2010.
25. Mehl KA, Davis JM, Clements JM, Berger FG, Pena MM, Carson JA. Decreased intestinal polyp multiplicity is related to exercise mode and gender in ApcMin/+ mice. J Appl Physiol 98: 2219-2225, 2005.
26. Moser AR, Pitot HC, Dove WF. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 247: 322-324, 1990.
27. Mustian KM, Morrow GR, Carroll JK, Figueroa-Moseley CD, Jean-Pierre P, Williams GC. Integrative nonpharmacologic behavioral interventions for the management of cancer-related fatigue. Oncologist 12, Suppl 1: 52-67, 2007.
28. Nader GA, Esser KA. Intracellular signaling specificity in skeletal muscle in response to different modes of exercise. J Appl Physiol 90: 1936-1942, 2001.
29. Nai YJ, Jiang ZW, Wang ZM, Li N, Li JS. Prevention of cancer cachexia by pyrrolidine dithiocarbamate (PDTC) in colon 26 tumor-bearing mice. JPEN J Parenter Enteral Nutr 31: 18-25, 2007.
30. Peterson JM, Guttridge DC. Skeletal muscle diseases, inflammation, and NF-kappaB signaling: insights and opportunities for therapeutic intervention. Int Rev Immunol 27: 375-387, 2008.
31. Pilegaard H, Ordway GA, Saltin B, Neufer PD. Transcriptional regulation of gene expression in human skeletal muscle during recovery from exercise. Am J Physiol Endocrinol Metab 279: E806-E814, 2000.
32. Pilegaard H, Saltin B, Neufer PD. Exercise induces transient transcriptional activation of the PGC-1alpha gene in human skeletal muscle. J Physiol 546: 851-858, 2003.
33. Puppa M, Gao S, Narsale A, Carson J. Skeletal muscle glycoprotein 130's role in Lewis Lung Carcinoma induced cachexia. FASEB J 28: 998-1009, 2014.
34. Puppa MJ, White JP, Velazquez KT, Baltgalvis KA, Sato S, Baynes JW, Carson JA. The effect of exercise on IL-6-induced cachexia in the Apc (Min/+) mouse. J Cachexia Sarcopenia Muscle 3: 117-137, 2012.
35. Risson V, Mazelin L, Roceri M, Sanchez H, Moncollin V, Corneloup C, Richard-Bulteau H, Vignaud A, Baas D, Defour A, Freyssenet D, Tanti JF, Le-Marchand-Brustel Y, Ferrier B, Conjard-Duplany A, Romanino K, Bauche S, Hantai D, Mueller M, Kozma SC, Thomas G, Ruegg MA, Ferry A, Pende M, Bigard X, Koulmann N, Schaeffer L, Gangloff YG. Muscle inactivation of mTOR causes metabolic and dys-trophin defects leading to severe myopathy. J Cell Biol 187: 859-874, 2009.
36. Russell AP, Hesselink MK, Lo SK, Schrauwen P. Regulation of metabolic transcriptional co-activators and transcription factors with acute exercise. FASEB J 19: 986-988, 2005.
37. Shi X, Leonard SS, Wang S, Ding M. Antioxidant properties of pyrro-lidine dithiocarbamate and its protection against Cr(VI)-induced DNA strand breakage. Ann Clin Lab Sci 30: 209-216, 2000.
38. Steinberg GR, Watt MJ, McGee SL, Chan S, Hargreaves M, Febbraio MA, Stapleton D, Kemp BE. Reduced glycogen availability is associated with increased AMPKalpha2 activity, nuclear AMPKalpha2 protein abundance, and GLUT4 mRNA expression in contracting human skeletal muscle. Appl Physiol Nutr Metab 31: 302-312, 2006.
39. Tan BH, Fearon KC. Cachexia: prevalence and impact in medicine. Curr Opin Clin Nutr Metab Care 11: 400-407, 2008.
40. Tisdale MJ. Cachexia in cancer patients. Nat Rev Cancer 2: 862-871, 2002.
41. Tisdale MJ. The "cancer cachectic factor". Support Care Cancer 11: 73-78, 2003.
42. Tisdale MJ. Mechanisms of cancer cachexia. Physiol Rev 89: 381-410, 2009.
43. Vavvas D, Apazidis A, Saha AK, Gamble J, Patel A, Kemp BE, Witters LA, Ruderman NB. Contraction-induced changes in acetyl-CoA carboxylase and 5'-AMP-activated kinase in skeletal muscle. J Biol Chem 272: 13255-13261, 1997.
44. White JP, Baltgalvis KA, Puppa MJ, Sato S, Baynes JW, Carson JA. Muscle oxidative capacity during IL-6-dependent cancer cachexia. Am J Physiol Regul Integr Comp Physiol 300: R201-R211, 2011.
45. White JP, Baynes JW, Welle SL, Kostek MC, Matesic LE, Sato S, Carson JA. The regulation of skeletal muscle protein turnover during the progression of cancer cachexia in the Apc(Min/+) mouse. PLos One 6: e24650, 2011.
46. White JP, Puppa MJ, Gao S, Sato S, Welle SL, Carson JA. Muscle mTORC1 suppression by IL-6 during cancer cachexia: A role for AMPK. Am J Physiol Endocrinol Metab 304: E1042-E1052, 2013.
47. White JP, Puppa MJ, Sato S, Gao S, Price RL, Baynes JW, Kostek MC, Matesic LE, Carson JA. IL-6 regulation on skeletal muscle mitochondrial remodeling during cancer cachexia in the ApcMin/+ mouse. Skelet Muscle 2: 14, 2012.
48. Zhang G, Jin B, Li YP. C/EBPbeta mediates tumour-induced ubiquitin ligase atrogin1/MAFbx upregulation and muscle wasting. EMBO J 30: 4323-4335, 2011.
49. Zhang G, Li YP. p38beta MAPK upregulates atrogin1/MAFbx by specific phosphorylation of C/EBPbeta. Skelet Muscle 2: 20, 2012.
50. Zhang G, Lin RK, Kwon YT, Li YP. Signaling mechanism of tumor cell-induced up-regulation of E3 ubiquitin ligase UBR2. FASEB J 27: 2893-2901, 2013.
51. Zinna EM, Yarasheski KE. Exercise treatment to counteract protein wasting of chronic diseases. Curr Opin Clin Nutr Metab Care 6: 87-93, 2003.